Mikhail Blagosklonny, Ph.D., is a leading scientist who is a Professor at the Roswell Park Cancer Institute. He conducts research into cancer and the aging process in order to help people live fuller, longer lives free of cancer and other age-related diseases. He is also the editor of a number of peer-reviewed medical journals such as the often cited Oncotarget.
Dr. Blagosklonny’s alma mater is First Pavlov State Medical University of St. Petersburg. He graduated from this Russian university with both his medical degree and Ph.D. in Cardiology and Experimental Medicine. He moved to the United States in 2002 when he was named an Associate Professor of Medicine by the New York Medical College. After he left this position he joined the Ordway Research Institute. It was in 2009 that he left to take his current position at the Roswell Park Cancer Institute which is located in Buffalo, New York. View Mikhail’s profile in LinkedIn
Dr. Mikhail Blagosklonny is well-known in the longevity research field as a huge proponent of researching Rapamycin as an effective way to slow or even halt the aging process. Rapamycin is a drug that is used to treat cancer; because of its possible role in TOR Signaling, it could also be a treatment for aging according to Dr. Blagosklonny’s extensive research in the drug.
While he has had more than 270 peer-reviewed research articles published himself, Dr. Mikhail Mikhail Blagosklonny is also very active as a medical journal founder and editor. He is involved with a number of peer-reviewed journals including Oncotarget, Aging, Oncoscience, Cancer Biology & Therapy, Autophagy, Cell Death and Differentiation and others as well. His ultimate goal is to provide people with a life that is free of disease. To do so he publishes research articles that are provided in a timely fashion and that are made widely available. Another mission of Dr. Blagosklonny’s is to remove the borders that tend to exist between clinical specialties and instead foster a more collaborative environment which leads to greater advances in the field of medicine. Visit ResearchGate.Net to learn more about Mikhail’s latest work.